% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{AfsharOromieh:119414,
      author       = {A. Afshar-Oromieh$^*$ and C. M. Zechmann$^*$ and A.
                      Malcher$^*$ and M. Eder$^*$ and M. Eisenhut$^*$ and H. G.
                      Linhart$^*$ and T. Holland-Letz$^*$ and B. A. Hadaschik and
                      F. Giesel$^*$ and J. Debus$^*$ and U. Haberkorn$^*$},
      title        = {{C}omparison of {PET} imaging with a (68){G}a-labelled
                      {PSMA} ligand and (18){F}-choline-based {PET}/{CT} for the
                      diagnosis of recurrent prostate cancer.30},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {41},
      number       = {1},
      issn         = {1619-7089},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2017-00156},
      pages        = {11 - 20},
      year         = {2014},
      abstract     = {Positron emission tomography (PET) with choline tracers has
                      found widespread use for the diagnosis of prostate cancer
                      (PC). However, choline metabolism is not increased in a
                      considerable number of cases, whereas prostate-specific
                      membrane antigen (PSMA) is overexpressed in most PCs.
                      Therefore, a (68)Ga-labelled PSMA ligand could be superior
                      to choline tracers by obtaining a high contrast. The aim of
                      this study was to compare such a novel tracer with standard
                      choline-based PET/CT.Thirty-seven patients with biochemical
                      relapse of PC [mean prostate-specific antigen (PSA) 11.1 ±
                      24.1 ng/ml, range 0.01-116] were retrospectively analysed
                      after (18)F-fluoromethylcholine and (68)Ga-PSMA PET/CT
                      within a time window of 30 days. Radiotracer uptake that was
                      visually considered as PC was semi-quantitatively analysed
                      by measuring the maximum standardized uptake values (SUVmax)
                      of the scans acquired 1 h after injection of (68)Ga-PSMA
                      complex solution (median 132 MBq, range 59-263 MBq) and
                      (18)F-fluoromethylcholine (median 237 MBq, range 114-374
                      MBq), respectively. In addition, tumour to background ratios
                      were calculated.A total of 78 lesions characteristic for PC
                      were detected in 32 patients using (68)Ga-PSMA PET/CT and 56
                      lesions were detected in 26 patients using choline PET/CT.
                      The higher detection rate in (68)Ga-PSMA PET/CT was
                      statistically significant (p=0.04). In five patients no
                      lesion was found with both methods. All lesions detected by
                      (18)F-fluoromethylcholine PET/CT were also seen by
                      (68)Ga-PSMA PET/CT. In (68)Ga-PSMA PET/CT SUVmax was clearly
                      (>10 $\%)$ higher in 62 of 78 lesions (79.1 $\%)$ and the
                      tumour to background ratio was clearly (>10 $\%)$ higher in
                      74 of 78 lesions (94.9 $\%)$ when compared to
                      (18)F-fluoromethylcholine PET/CT.(68)Ga-PSMA PET/CT can
                      detect lesions characteristic for PC with improved contrast
                      when compared to standard (18)F-fluoromethylcholine PET/CT,
                      especially at low PSA levels.},
      keywords     = {Antigens, Surface (NLM Chemicals) / Gallium Radioisotopes
                      (NLM Chemicals) / Ligands (NLM Chemicals) /
                      fluoromethylcholine (NLM Chemicals) / Glutamate
                      Carboxypeptidase II (NLM Chemicals) / glutamate
                      carboxypeptidase II, human (NLM Chemicals) / Choline (NLM
                      Chemicals)},
      cin          = {E060 / E030 / G100 / C060 / E050},
      ddc          = {610},
      cid          = {I:(DE-He78)E060-20160331 / I:(DE-He78)E030-20160331 /
                      I:(DE-He78)G100-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)E050-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:24072344},
      pmc          = {pmc:PMC3843747},
      doi          = {10.1007/s00259-013-2525-5},
      url          = {https://inrepo02.dkfz.de/record/119414},
}